Hemlibra FDA Approval History
FDA Approved: Yes (First approved November 16, 2017)
Brand name: Hemlibra
Generic name: emicizumab-kxwh
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Hemophilia A with Inhibitors, Hemophilia A
Hemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody indicated to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
Development Timeline for Hemlibra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.